Shire Pharmaceuticals has received FDA approval for three additional dosage strengths of Vyvanse (lisdexamfetamine dimesylate capsules). The 20mg, 40mg, and 60mg capsules will be available in addition to the 30mg, 50mg, and 70mg strengths already on the market. Vyvanse is indicated for the treatment of Attention-deficit/hyperactivity disorder (ADHD) in children 6-12 years of age. The additional strengths are expected to be available in pharmacies in the second quarter of 2008.
For more information call (800) 828-2088 or visit www.vyvanse.com.